Lipella Pharmaceuticals Inc. (LIPO) stock
LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.27KP/E –Yield –
Lipella Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lipella Pharmaceuticals's operating income for the twelve months ending Sep 30, 2025 was -$5.41M. For fiscal 2024 it was -$5.08M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$5.08M | – |
| FY2023 | Dec 31, 2023 | -$4.75M | – |
| FY2022 | Dec 31, 2022 | -$2.59M | – |
| FY2021 | Dec 31, 2021 | -$1.92M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$1.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$952.19K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$729.59K | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$359.26K | – |
| Q3 FY2022 | Sep 30, 2022 | -$712.64K | – |
| Q2 FY2022 | Jun 30, 2022 | -$781.15K | – |
| Q1 FY2022 | Mar 31, 2022 | -$736.66K | – |
See a number that looks wrong?